We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Briacell Therapeutics Corp (BCT) NPV

Sell:0.94 CAD Buy:1.13 CAD Change: 0.06 CAD (6.19%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Sell:0.94 CAD
Buy:1.13 CAD
Change: 0.06 CAD (6.19%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
Sell:0.94 CAD
Buy:1.13 CAD
Change: 0.06 CAD (6.19%)
Market closed |  Prices as at close on 24 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops immunotherapies to transform cancer care. The Company’s lead drug candidate, Bria-IMT, is a cell-based patented immunotherapy that stimulates a patient’s own cancer fighting cells to attack and destroy breast cancer tumors. The Company is advancing its targeted immunotherapy program by prioritizing a Phase II clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor. The Company is focused on conducting a Phase I/IIa clinical trial of Bria-IMT in a combination study with Incyte’s immune PD-1 inhibitor, retifanlimab, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized approach to whole cell cancer immunotherapy. The Bria-OTS immunotherapy is based on a patient’s HLA-type. Its pipeline also includes Bria-Pros, Bria-Lung, Bria-Mel and sCD80, which are in development to treat various cancers.

Contact details

3rd Floor
Bellevue Centre,, 235-15th Str
V7T 2X1
+1 (604) 9211810

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
17.03 million CAD
Shares in issue:
18.28 million
Toronto Stock Exchange
Canadian dollars

Key personnel

  • William Williams
    President, Chief Executive Officer, Director
  • Gadi Levin
    Chief Financial Officer, Corporate Secretary
  • Miguel Lopez-Lago
    Chief Scientific Officer
  • Giuseppe Del Priore
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.